Fireside Chat: Novo Nordisk + Akero: Behind the Scenes of a Landmark Deal
June 24, 2026
28ABCDE
Type: Super Session
Focus Area:
Business Development and Investment
This session will shed light on the recent acquisition of Akero Therapeutics by Novo Nordisk. The two panelists played a key role in forging this deal and will share their perspective on the journey throughout the process. This acquisition exemplifies how Business Development fuels Novo Nordisk’s mission to address the unmet needs of the many people living obesity, diabetes and their associated comorbidities – like MASH, a condition affecting more than 250 million people worldwide.
Moderator
Speakers
Sponsored by:
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}